Loading...
•
Sep 30, 2022
Oncology Institute Q3 2022 Earnings Report
The Oncology Institute's value-based care model and growth strategy were highlighted.
Key Takeaways
The Oncology Institute's investor presentation highlighted their position as a leading value-based oncology care platform, emphasizing their disruptive model, growth opportunities, and financial overview, including a revenue guidance of $245 to $250 million for 2022.
The Oncology Institute (TOI) is disrupting oncology care with a unique value-based model.
TOI's technology platform standardizes and aligns care delivery at scale.
The company has demonstrated new market exportability and has predictable, repeatable, and scalable growth.
Tremendous near-term and long-term growth opportunities exist for TOI.
Oncology Institute
Oncology Institute
Oncology Institute Revenue by Segment
Revenue by Segment
Patient Services Revenue
CapyFin.comDispensary Revenue
CapyFin.com Forward Guidance
The Oncology Institute projects continued growth and profitability, driven by value-based care contracts, expansion into new markets, and strategic acquisitions.
Positive Outlook
- New markets launch with FFS + Gainshare
- Acquisition CAGR (Top-line): 18%
- Acquisition EBITDA accretive: Year 1
- DeNovo CAGR (Top-line): 53%
- Conversion to Capitated Contracts by year 4: enabling Gross Margins >25%
Challenges Ahead
- Adjusted EBITDA and Net Income Protability projected in 2024
- Acquisitions
- De Novo Growth
- Operating Losses
- Working Capital (predominantly funding A/R)
Revenue & Expenses
Visualization of income flow from segment revenue to net income